BTAIQ BioXcel Therapeutics, Inc.: institutional ownership and insider trading
44 funds reported holding $9.13M of BioXcel Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $1.04M, with 10 new positions and 3 funds selling out; over the last 12 months insiders bought $0 and sold $43.2K on the open market.
Famous investors holding BTAIQ
- Howard Marks (Oaktree Capital Management): $1.95M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $2.98M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $210K, 0.0% of the portfolio
Largest institutional holders of BTAIQ
- MILLENNIUM MANAGEMENT LLC — $2.98M
- OAKTREE CAPITAL MANAGEMENT LP — $1.95M
- VANGUARD CAPITAL MANAGEMENT LLC — $1.30M
- VANGUARD GROUP INC — $468K
- Oaktree Fund Advisors, LLC — $346K
- GEODE CAPITAL MANAGEMENT, LLC — $342K
- BlackRock, Inc. (BLK) — $253K
- UBS Group AG (UBS) — $223K
- CITADEL ADVISORS LLC — $210K
- VANGUARD FIDUCIARY TRUST CO — $193K
Recent BTAIQ insider trades
- May 20, 2026: Mehta Vimal sold 19,419 shares ($21.2K)
- May 20, 2026: Steinhart Richard I sold 6,845 shares ($7.46K)
- May 20, 2026: Rodriguez Javier sold 6,560 shares ($7.09K)
- May 20, 2026: Yocca Frank sold 6,845 shares ($7.46K)
5%+ owners
- Millennium Management LLC: 8.4% (Schedule 13G/A, filed Feb 9, 2026)